• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed

    2/12/21 5:16:00 PM ET
    $PAND
    Get the next $PAND alert in real time by email
    SC 13G 1 d104636dsc13g.htm SC 13G SC 13G

     

     

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    Schedule 13G

    (Rule 13d-102)

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED

    PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO 13d-2 (b)

    (Amendment No.     )

     

     

    Pandion Therapeutics, Inc.

    (Name of Issuer)

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)

    698340 10 6

    (CUSIP Number)

    December 31, 2020

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐

    Rule 13d-1(b)

     

    ☐

    Rule 13d-1(c)

     

    ☒

    Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

    (Continued on following pages)


    CUSIP #698340 10 6      

     

    1     

    NAME OF REPORTING PERSONS

     

    Polaris Partners VIII, L.P.

    2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)  ☐        (b)  ☒

     

    3  

    SEC USE ONLY

     

    4  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5     

    SOLE VOTING POWER

     

    0

       6   

    SHARED VOTING POWER

     

    3,090,800 (1)

       7   

    SOLE DISPOSITIVE POWER

     

    0

       8   

    SHARED DISPOSITIVE POWER

     

    3,090,800 (1)

    9    

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    3,090,800 (1)

    10    

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

    ☐

    11  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    10.5% (2)

    12  

    TYPE OF REPORTING PERSON

     

    PN

     

    (1)

    All such shares are held of record by PP VIII (as defined in Item 2(A) below). PPGP VIII (as defined in Item 2(A) below), the general partner of PP VIII, may be deemed to have voting, investment and dispositive power with respect to these securities. David Barrett, Brian Chee, Amir Nashat and Bryce Youngren are the managing members of PPGP VIII and may each be deemed to share voting, investment and dispositive power with respect to these securities. Alan Crane, a member of the Issuer’s board of directors, holds an interest in PPGP VIII and may be deemed to share voting, investment and dispositive power with respect to these securities.

    (2)

    Based on 29,519,902 shares of Common Stock outstanding as of November 12, 2020, as reported on the Issuer’s Quarterly Report on Form 10-Q, for the quarter ended September 30, 2020, as filed with the United States Securities and Exchange Commission on November 16, 2020 (the “Form 10-Q”).


    CUSIP #698340 10 6      

     

    1     

    NAME OF REPORTING PERSONS

     

    Polaris Entrepreneurs’ Fund VIII, L.P.

    2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)  ☐        (b)  ☒

     

    3  

    SEC USE ONLY

     

    4  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5     

    SOLE VOTING POWER

     

    0

       6   

    SHARED VOTING POWER

     

    110,622 (1)

       7   

    SOLE DISPOSITIVE POWER

     

    0

       8   

    SHARED DISPOSITIVE POWER

     

    110,622 (1)

    9    

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    110,622 (1)

    10    

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

    ☐

    11  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    0.4% (2)

    12  

    TYPE OF REPORTING PERSON

     

    PN

     

    (1)

    All such shares are held of record by PEF VIII (as defined in Item 2(a) below). PPGP VIII, the general partner of PEF VIII, may be deemed to have voting, investment and dispositive power with respect to these securities. David Barrett, Brian Chee, Amir Nashat and Bryce Youngren are the managing members of PPGP VIII and may each be deemed to share voting, investment and dispositive power with respect to these securities. Alan Crane, a member of the Issuer’s board of directors, holds an interest in PPGP VIII and may be deemed to share voting, investment and dispositive power with respect to these securities.

    (2)

    Based on 29,519,902 shares of Common Stock outstanding as of November 12, 2020, as reported on the Issuer’s Form 10-Q.


    CUSIP #698340 10 6      

     

    1     

    NAME OF REPORTING PERSONS

     

    Polaris Partners GP VIII, L.L.C.

    2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)  ☐        (b)  ☒

     

    3  

    SEC USE ONLY

     

    4  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5     

    SOLE VOTING POWER

     

    0

       6   

    SHARED VOTING POWER

     

    3,201,422 (1)

       7   

    SOLE DISPOSITIVE POWER

     

    0

       8   

    SHARED DISPOSITIVE POWER

     

    3,201,422 (1)

    9    

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    3,201,422 (1)

    10    

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

    ☐

    11  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    12.7% (2)

    12  

    TYPE OF REPORTING PERSON

     

    OO

     

    (1)

    3,090,800 of such shares are held of record by PP VIII and 110,622 of such shares are held of record by PEF VIII. PPGP VIII, the general partner of each of PP VIII and PEF VIII, may be deemed to have voting, investment and dispositive power with respect to these securities. David Barrett, Brian Chee, Amir Nashat and Bryce Youngren are the managing members of PPGP VIII and may each be deemed to share voting, investment and dispositive power with respect to these securities. Alan Crane, a member of the Issuer’s board of directors, holds an interest in PPGP VIII and may be deemed to share voting, investment and dispositive power with respect to these securities.

    (2)

    Based on 29,519,902 shares of Common Stock outstanding as of November 12, 2020, as reported on the Issuer’s Form 10-Q.


    SCHEDULE 13G

    CUSIP #698340 10 6      

     

    ITEM 1(A).

    NAME OF ISSUER

    Pandion Therapeutics, Inc. (the “Issuer”)

     

    ITEM 1(B).

    ADDRESS OF ISSUER’S PRINCIPAL EXECUTIVE OFFICES

    134 Coolidge Avenue

    Watertown, MA 02472

     

    ITEM 2(A).

    NAME OF PERSONS FILING

    This Schedule 13G is being filed on behalf of each of the following persons: Polaris Partners VIII, L.P. (“PP VIII”), Polaris Entrepreneurs’ Fund VIII, L.P. (“PEF VIII”), Polaris Partners GP VIII, L.L.C. (“PPGP VIII” and together with PP VIII and PEF VIII, the “Reporting Entities”). David Barrett, Brian Chee, Amir Nashat and Bryce Youngren are the managing members of PPGP VIII. Alan Crane, a member of the Issuer’s board of directors, holds an interest in PPGP VIII. To the extent feasible, PEF VIII invests alongside PP VIII.

     

    ITEM 2(B).

    ADDRESS OR PRINCIPAL OFFICE

    The address for each of the Reporting Entities is:

    c/o Polaris Partners

    One Marina Park Drive, 10th Floor

    Boston, MA 02210

     

    ITEM 2(C).

    CITIZENSHIP

    PP VIII and PEF VIII are limited partnerships organized under the laws of the State of Delaware. PPGP VIII is a limited liability company organized under the laws of the State of Delaware.

     

    ITEM 2(D).

    TITLE OF CLASS OF SECURITIES

    Common Stock, par value $0.001 per share


    CUSIP #698340 10 6      

     

    ITEM 2(E)

    CUSIP NUMBER

    698340 10 6

     

    ITEM 3.

    IF THIS STATEMENT IS FILED PURSUANT TO RULE 13D-1(B), OR 13D-2(B) OR (C), CHECK WHETHER THE PERSON FILING IS A:

    Not applicable.

     

    ITEM 4.

    OWNERSHIP

    The following information with respect to the ownership of the common stock of the Issuer by the Reporting Entities filing this Statement is provided as of December 31, 2020:

    (a) Amount beneficially owned:

    See Row 9 of cover page for each Reporting Entity and the corresponding footnotes.*

    (b) Percent of Class:

    See Row 11 of cover page for each Reporting Entity and the corresponding footnotes.*

    (c) Number of shares as to which such person has:

    (i) Sole power to vote or to direct the vote:

    See Row 5 of cover page for each Reporting Entity and the corresponding footnotes.*

    (ii) Shared power to vote or to direct the vote:

    See Row 6 of cover page for each Reporting Entity and the corresponding footnotes.*

    (iii) Sole power to dispose or to direct the disposition of:

    See Row 7 of cover page for each Reporting Entity and the corresponding footnotes.*

    (iv) Shared power to dispose or to direct the disposition of:

    See Row 8 of cover page for each Reporting Entity and the corresponding footnotes.*

     

    *

    Each Reporting Entity disclaims beneficial ownership as to such securities, except to the extent its pecuniary interest therein.

     

    ITEM 5.

    OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS

    Not applicable.

     

    ITEM 6.

    OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.

    Under certain circumstances set forth in the limited partnership agreements of each of PP VIII and PEF VIII, and the limited liability company agreement of PPGP VIII, the general and limited partners or members of each such entity, as applicable, may be deemed to have the right to receive dividends from, or the proceeds from, the sale of shares of the issuer owned by each such entity of which they are a partner or member, as applicable.

     

    ITEM 7.

    IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY

    Not applicable.


    CUSIP #698340 10 6      

     

    ITEM 8.

    IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.

    See Exhibit A.

     

    ITEM 9.

    NOTICE OF DISSOLUTION OF GROUP.

    Not applicable

     

    ITEM 10.

    CERTIFICATION.

    Not applicable

    Material to be Filed as Exhibits.

    Exhibit A – Agreement regarding filing of joint Schedule 13G.

    Exhibit B – Power of Attorney (Polaris Partners GP VIII, L.L.C.)


    CUSIP #698340 10 6      

     

    SIGNATURES

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date: February 12, 2021

     

    POLARIS PARTNERS VIII, L.P.
    By:   Polaris Partners GP VIII, L.L.C.
    By:  

    **

      Authorized Signatory
    POLARIS ENTREPRENEURS’ FUND VIII, L.P.
    By:   Polaris Partners GP VIII, L.L.C.
    By:  

    **

      Authorized Signatory
    POLARIS PARTNERS GP VIII, L.L.C.
    By:  

    **

      Authorized Signatory

     

    *By:

     

    /s/ Lauren Crockett

    Name:

     

    Lauren Crockett

     

    Attorney-in-Fact

    [*This Schedule 13G was executed pursuant to a Power of Attorney. Note that copies of the applicable Powers of Attorney are already on file with the appropriate agencies.]

    [**This Schedule 13G was executed pursuant to a Power of Attorney. Note that copies of the applicable Powers of Attorney included as exhibits to this Schedule 13G.]

    Get the next $PAND alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PAND

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PAND
    SEC Filings

    See more
    • SEC Form 15-12B filed by Pandion Therapeutics Inc.

      15-12B - Pandion Therapeutics, Inc. (0001807901) (Filer)

      4/12/21 6:54:59 AM ET
      $PAND
    • SEC Form EFFECT filed by Pandion Therapeutics Inc.

      EFFECT - Pandion Therapeutics, Inc. (0001807901) (Filer)

      4/6/21 12:15:17 AM ET
      $PAND
    • SEC Form EFFECT filed by Pandion Therapeutics Inc.

      EFFECT - Pandion Therapeutics, Inc. (0001807901) (Filer)

      4/6/21 12:15:16 AM ET
      $PAND

    $PAND
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Merck Completes Acquisition of Pandion Therapeutics

      KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the successful completion of the cash tender offer, through a subsidiary, for all of the outstanding shares of common stock of Pandion Therapeutics, Inc. (Nasdaq: PAND) at a purchase price of $60 per share. As of the tender offer expiration, 27,770,123 shares of common stock of Pandion were validly tendered and not withdrawn from the tender offer, representing approximately 88.6% percent of the outstanding common stock of Pandion on a fully diluted basis. All such shares have been accepted for payment in accordance with the terms of the tender offer, and Merck exp

      4/1/21 8:30:00 AM ET
      $PAND
    • Merck Begins Tender Offer to Acquire Pandion Therapeutics

      KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, is commencing today, through a subsidiary, a cash tender offer to purchase all outstanding shares of common stock of Pandion Therapeutics, Inc. (Nasdaq: PAND). On Feb. 25, 2021, Merck announced its intent to acquire Pandion. Upon the successful closing of the tender offer, stockholders of Pandion will receive $60 in cash for each share of Pandion common stock validly tendered and not validly withdrawn in the offer, without interest and less any required withholding taxes. Following the purchase of shares in the tender offer, Pandion will become a subsidiary of Merck. Merck will

      3/4/21 6:45:00 AM ET
      $MRK
      $PAND
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Merck to Acquire Pandion Therapeutics

      KENILWORTH, N.J & WATERTOWN, Mass.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Pandion Therapeutics, Inc. (Nasdaq: PAND) today announced that the companies have entered into a definitive agreement, under which Merck, through a subsidiary, will acquire Pandion, a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet needs of patients living with autoimmune diseases, for $60 per share in cash. This represents an approximate total equity value of $1.85 billion. “This acquisition builds upon Merck’s strategy to identify and secure candidates with differentiated and potentially foundational charac

      2/25/21 6:45:00 AM ET
      $MRK
      $PAND
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PAND
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: L. Joanne Viney decreased direct ownership by 100% to 0 units

      4 - Pandion Therapeutics, Inc. (0001807901) (Issuer)

      4/1/21 7:59:21 PM ET
      $PAND
    • SEC Form 4: Vikas Goyal decreased direct ownership by 100% to 0 units

      4 - Pandion Therapeutics, Inc. (0001807901) (Issuer)

      4/1/21 7:58:39 PM ET
      $PAND
    • SEC Form 4: L Alan Crane decreased direct ownership by 100% to 0 units

      4 - Pandion Therapeutics, Inc. (0001807901) (Issuer)

      4/1/21 7:57:32 PM ET
      $PAND

    $PAND
    Financials

    Live finance-specific insights

    See more

    $PAND
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Merck Completes Acquisition of Pandion Therapeutics

      KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the successful completion of the cash tender offer, through a subsidiary, for all of the outstanding shares of common stock of Pandion Therapeutics, Inc. (Nasdaq: PAND) at a purchase price of $60 per share. As of the tender offer expiration, 27,770,123 shares of common stock of Pandion were validly tendered and not withdrawn from the tender offer, representing approximately 88.6% percent of the outstanding common stock of Pandion on a fully diluted basis. All such shares have been accepted for payment in accordance with the terms of the tender offer, and Merck exp

      4/1/21 8:30:00 AM ET
      $PAND
    • SVB Leerink resumed coverage on Pandion Therapeutics with a new price target

      SVB Leerink resumed coverage of Pandion Therapeutics with a rating of Market Perform and set a new price target of $60.00

      3/4/21 8:24:57 AM ET
      $PAND
    • Morgan Stanley resumed coverage on Pandion Therapeutics with a new price target

      Morgan Stanley resumed coverage of Pandion Therapeutics with a rating of Equal Weight and set a new price target of $60.00 from $25.00 previously

      3/4/21 8:24:08 AM ET
      $PAND
    • Pandion Therapeutics downgraded by Morgan Stanley with a new price target

      Morgan Stanley downgraded Pandion Therapeutics from Overweight to Equal-Weight and set a new price target of $60.00 from $25.00 previously

      2/26/21 9:18:02 AM ET
      $PAND

    $PAND
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Pandion Therapeutics Inc. (Amendment)

      SC 13G/A - Pandion Therapeutics, Inc. (0001807901) (Subject)

      5/17/21 4:35:46 PM ET
      $PAND
    • SEC Form SC 13D/A filed by Pandion Therapeutics Inc. (Amendment)

      SC 13D/A - Pandion Therapeutics, Inc. (0001807901) (Subject)

      4/8/21 5:24:29 PM ET
      $PAND
    • SEC Form SC 13D/A filed by Pandion Therapeutics Inc. (Amendment)

      SC 13D/A - Pandion Therapeutics, Inc. (0001807901) (Subject)

      4/2/21 9:54:00 AM ET
      $PAND

    $PAND
    Leadership Updates

    Live Leadership Updates

    See more
    • NodThera Appoints Chief Medical Officer and Chief Financial Officer

      CAMBRIDGE, England & BOSTON & SEATTLE--(BUSINESS WIRE)--NodThera, a biotechnology company developing a new class of medicines that inhibit the NLRP3 inflammasome to treat chronic inflammation, today announced the expansion of its senior leadership team with the appointments of Donald Johns, M.D., as Chief Medical Officer and Katina Dorton, J.D., MBA, as Chief Financial Officer. Dr. Johns is an accomplished drug development leader and board-certified clinical neurologist who previously served as Chief Medical Officer and Executive Vice President of Medical and Scientific Affairs at Syntimmune, prior to the company’s acquisition by Alexion Pharmaceuticals. Ms. Dorton is a recognized

      12/15/20 8:00:00 AM ET
      $PAND
      $FULC
      $ECOL
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Environmental Services
      Public Utilities
    • Pandion Therapeutics Appoints Katina Dorton to its Board of Directors

      WATERTOWN, Mass., Dec. 03, 2020 (GLOBE NEWSWIRE) -- Pandion Therapeutics, Inc. (Nasdaq: PAND), a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet needs of patients living with autoimmune diseases, today announced the appointment of Katina Dorton, J.D., M.B.A., to Pandion’s board of directors and as chair of the audit committee. Ms. Dorton assumes the position of chair of the audit committee from Christopher Fuglesang, Ph.D., J.D., who will continue to serve as a member of the board and audit committee. Mitchell Mutz, Ph.D., resigned from the Company’s board on December 2, 2020. “Ms. Dorton brings to Pandion over two decades of financial expe

      12/3/20 8:00:00 AM ET
      $PAND
      $ECOL
      $MS
      $FULC
      Environmental Services
      Public Utilities
      Investment Bankers/Brokers/Service
      Finance